Conclusions
cataract, NA-AION
CATARACT
In patients with acute NA-AION, intravitreal application of allogeneic bone marrow-derived mesenchymal stem cells appeared to be safe. This clinical trial showed that the injection of BMSCs to treat acute NA-AION was well tolerated. Nevertheless, one patient developed an ERM with bad outcome probably related to the fact that the patient did not agree to be operated on before, and another one showed a transient deposit in the retrolental space which possibly was an aggregate of cells that vanished spontaneously leaving a subcapsular cataract. The positive risk/benefit analysis of this trial motivated the design of a multicenter study that will include more patients that will be performed in four Spanish centers.